AlphaYou
Overview
Smart money at a glance
Filings to Oct 12, 2026Net buying: insiders sold $0 and bought $835K on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- +$835K netNet buying
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, latest quarter
- NoneNo large changes
Market overview
Fundamentals May 24- 52-wk high
- $0.11
- 52-wk low
- $0.03
- Mkt cap
- $2.6M
- P/E
- 0.1x
- Beta
- 1.65
- P/B
- 15.8x
- Profit margin
- +0.0%
- Op margin
- +0.0%
- ROE
- -2059.0%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about HEPA filings
Are insiders buying or selling Hepion Pharmaceuticals Inc (HEPA) stock?
Net buying: insiders sold $0 and bought $835K of HEPA stock on the open market in the 90 days to Oct 12, 2026, according to SEC Form 4 filings. The largest was LoPriore, Vincent S (Executive Chairman), who bought $500K. The latest filing was on Oct 2, 2026.
Which members of Congress have traded HEPA recently?
None. No member of Congress disclosed a HEPA trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this HEPA smart-money data?
This summary uses filings available on Oct 12, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
Insiders have been net buying.
What insiders are doing
Buys (3)
- FD
Fisher Danina
$10K
bought
- LV
Lopriore Vincent S
$500K
bought
- SG
Stetz Gary S.
$100K
bought
How top traders are positioned
No tracked top-trader positions in HEPA right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Results versus expectations
No reported figure for the latest quarter.
Company release linked above, where available
Previous reports
All values in USD| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2025 | Aug 15, 2025 | Unavailable | - | Unavailable | Unavailable |
| Mar 31, 2025 | Apr 8, 2025 | -$11.11 / -$1.97Alpha Vantage | -$9.14 miss | Unavailable | Unavailable |
| Dec 31, 2024 | Feb 26, 2025 | Unavailable | - | Unavailable | Unavailable |
| Sep 30, 2024 | Nov 14, 2024 | Unavailable | - | Unavailable | Unavailable |
| Jun 30, 2024 | Aug 13, 2024 | Unavailable | - | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
What the street expects next
Financials
Is the business strong?
Fairly priced and running thin margins.
- Net margin
- 0.0%
- P/E
- 0.07
- Market cap
- $3M
Valuation
- P/B15.85
Quality
- Operating margin0.0%
- ROE-2059.0%
- ROA-100.4%
Growth
- Beta1.65
Technicals
Price structure
Market data unavailable.